New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more: The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- Study: 20% of glioblastomas are fueled by overactive mitochondriaon January 11, 2021 at 3:52 pm
A new study has found that up to 20% of glioblastomas--an aggressive brain cancer--are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
- One in five brain cancers fueled by overactive mitochondriaon January 11, 2021 at 9:27 am
A new study has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
- Novel RNA factors may help cancer cells thriveon January 10, 2021 at 10:13 am
Recent work pinpoints critical changes in an enzyme known as DICER, which create a cascade of effects on this microRNAome. The team identified primary actors circ2082, a circular RNA, and RBM3, an RNA ...
- Nuclear DICER complex disrupts cytoplasmic microRNAome in glioblastoma cancer cellson January 9, 2021 at 9:01 pm
Like Peter Pan, some cells never grow up. In cancer, undifferentiated stem cells may help tumors such as glioblastoma become more aggressive than other forms of the disease.
- The Glioblastoma Research Organization Teams Up With Best Wellness Brands In The Market To Celebrate Research Partnerson January 9, 2021 at 3:28 am
Partners like Memorial Sloan Kettering, Md Anderson, Lenox Hill, and U Miami health receive thank you boxes with 20+ top wellness brands from the GBMRO.
- First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102 (Enzastaurin) in Patients with Newly-Diagnosed Glioblastoma (GBM)on January 8, 2021 at 10:55 pm
Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced dosing of the first patient in its biomarker guided Phase 3 clinical study ...
- UMN Begins First-In-Human Clinical Trial For ‘Innovative’ Glioblastoma Treatmenton January 7, 2021 at 11:42 am
The University of Minnesota on Thursday announced that a promising new brain cancer clinical trial is underway. It’s Phase I of the first-in-human trial, and university physicians and scientists are ...
- U of M begins Phase I of first-in-human clinical trial for glioblastomaon January 7, 2021 at 10:33 am
The trial is led by neuro-oncologist Elizabeth Neil, an assistant professor in the Department of Neurology at the University of Minnesota Medical School.
- Glioblastoma Linked with Brain Healing after Traumaon January 5, 2021 at 5:00 am
Researchers say findings point to "swathe" of potential therapeutic targets and precision medicine for glioblastoma.
- How brain inflammation and healing is pointing to new glioblastoma targetson January 4, 2021 at 10:10 am
Canadian researchers discovered a state of “injury response” in the brain that's marked by signals of inflammation and immune activity and that can give rise to glioblastoma. They believe the details ...
via Bing News